Abstract:The generation of effective levels of antigen-specific immunity at the mucosal sites of pathogen entry is a key goal for vaccinologists. We explored topical vaginal application as an approach to initiate local antigen-specific immunity, enhance previously existing systemic immunity or re-target responses to the mucosae. To deliver a protein vaccine formulation to the vaginal mucosal surface, we used a novel vaginal ring device comprising a silicone elastomer body into which three freeze-dried, rod-shaped, hydroxypropylmethylcellulose inserts were incorporated. Each rod contained recombinant HIV-1 CN54gp140 protein (167μg)±R848 (167μg) adjuvant. The inserts were loaded into cavities within each ring such that only the ends of the inserts were initially exposed. Sheep received a prime-boost vaccination regime comprising intramuscular injection of 100μg CN54gp140+200μg R848 followed by three successive ring applications of one week duration and separated by one month intervals. Other sheep received only the ring devices without intramuscular priming. Serum and vaginal mucosal fluids were sampled every two weeks and analysed by CN54gp140 ELISA and antigen-specific B cells were measured by flow cytometry at necropsy. Vaccine antigen-specific serum antibody responses were detected in both the intramuscularly-primed and vaginal mucosally-primed groups. Those animals that received only vaginal vaccinations had identical IgG but superior IgA responses. Analysis revealed that all animals exhibited mucosal antigen-specific IgG and IgA with the IgA responses 30-fold greater than systemic levels. Importantly, very high numbers of antigen-specific B cells were detected in local genital draining lymph nodes. We have elicited local genital antigen-specific immune responses after topical application of an adjuvanted antigen formulation within a novel vaginal ring vaccine release device. This regimen and delivery method elicited high levels of antigen-specific mucosal IgA and large numbers of local antigen-reactive B cells, both likely essential for effective mucosal protection.

Local gene expression and immune responses of vaginal DNA vaccination using a needle-free injector

Mucus-penetrating Nonviral Gene Vaccine Processed in the Epithelium for Inducing Advanced Vaginal Mucosal Immune Responses

A Promising Needle-Free Pyro-Drive Jet Injector for Augmentation of Immunity by Intradermal Injection as a Physical Adjuvant

Induction of potent antitumor immunity by intradermal DNA injection using a novel needle‐free pyro‐drive jet injector

Intravaginal immunisation using a novel antigen-releasing ring device elicits robust vaccine antigen-specific systemic and mucosal humoral immune responses

Microneedles Improve the Immunogenicity of DNA Vaccines.

Enhanced immunity in intradermal vaccination by novel hollow microneedles

Molecular investigations into vaginal immunization with HIV gp41 antigenic construct H4A in a quick release solid dosage form

Improved Influenza Vaccination in the Skin Using Vaccine Coated Microneedles

Local Response to Microneedle-Based Influenza Immunization in the Skin

Engineering intravaginal vaccines to overcome mucosal and epithelial barriers

Improved DNA Vaccine Delivery with Needle-Free Injection Systems

Sublingual antigen delivery: a solution for needle-free HIV vaccination

HER2/neu DNA vaccination by intradermal gene delivery in a mouse tumor model

Live-Attenuated VEEV Vaccine Delivered by iDNA Using Microneedles Is Immunogenic in Rabbits

Enhancing humoral immunity via sustained-release implantable microneedle patch vaccination

DNA Vaccine-Encapsulated Virus-Like Particles Derived from an Orally Transmissible Virus Stimulate Mucosal and Systemic Immune Responses by Oral Administration

Influenza Immunization with Trehalose-Stabilized Virus-Like Particle Vaccine Using Microneedles.

Intradermal Vaccination with Influenza Virus-Like Particles by Using Microneedles Induces Protection Superior to That with Intramuscular Immunization

Intradermal delivery of recombinant vaccinia virus vector DIs induces gut-mucosal immunity

Microneedle Delivery of Trivalent Influenza Vaccine to the Skin Induces Long-Term Cross-Protection